- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| XYTOS INTERNATIONAL Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SURROZEN | 31,570 | +79,38 % | Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy | ||
| QIAGEN | 38,835 | +0,84 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen vor Zahlen zum dritten Quartal mit einem Kursziel von 47 Euro auf "Buy" belassen. Jan Koch rechnet in seinem am Donnerstag... ► Artikel lesen | |
| APIMEDS PHARMACEUTICALS US | 5,700 | +204,00 % | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 3,735 | -7,78 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| IMMUNOME | 22,540 | -12,47 % | Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027 | ||
| PRAXIS PRECISION MEDICINES | 280,78 | -6,61 % | H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential | ||
| SUMMIT THERAPEUTICS | 16,470 | -3,80 % | Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock | ||
| BEAM THERAPEUTICS | 24,380 | -5,98 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| CG ONCOLOGY | 68,62 | -11,73 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| COGENT BIOSCIENCES | 30,945 | -5,16 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 101,10 | -8,65 % | Citizens reiterates Market Perform on Inhibrx Biosciences stock | ||
| ARCUTIS BIOTHERAPEUTICS | 25,940 | -6,62 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,930 | -6,27 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| ERASCA | 13,995 | -10,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| IMMUNOVANT | 34,130 | -8,47 % | IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down |
XYTOS INTERNATIONAL INC gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XYTOS INTERNATIONAL INC finden Sie auf Wallstreet Online.